Get started
Work

Abstract PS5-07-15: A randomized phase II study to evaluate the efficacy and safety of Trastuzumab deruxtecan (T-DXd) versus CDK4/6 inhibitor-based endocrine therapy as first-line therapy of hormone receptor-positive (HR+) and HER2-low/ultralow advanced breast cancer (ABC) patients classified as non-luminal subtype according to gene expression profiling: the PONTIAC study

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps5-07-15
Authors: J. Cortes, Á. Guerrero-Zotano, M. Gion, M. Campolier, M. Verbeni, S. Iacobucci, A. del Pino, S. Santasusagna, K. Jhaveri, A. Bardia, C. Barrios, S. Franco Millan, G. Antonarelli, S. Kümmel, P. Cottu, J. Pérez-García, A. Llombart-Cussac
Institutions: Fundación Instituto Valenciano de Oncología, Hospital Universitario Ramón y Cajal, MedSIR (Spain), Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Latin American Cooperative Oncology Group (LACOG), University of Milan, Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Institut Curie, Universidad Cardenal Herrera CEU, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129578762
Cites:
Cited by:
Related to: